CA2368593A1 - Anti-inflammatory therapy for inflammatory mediated infection - Google Patents

Anti-inflammatory therapy for inflammatory mediated infection Download PDF

Info

Publication number
CA2368593A1
CA2368593A1 CA002368593A CA2368593A CA2368593A1 CA 2368593 A1 CA2368593 A1 CA 2368593A1 CA 002368593 A CA002368593 A CA 002368593A CA 2368593 A CA2368593 A CA 2368593A CA 2368593 A1 CA2368593 A1 CA 2368593A1
Authority
CA
Canada
Prior art keywords
inflammatory
viral
agent
hiv
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002368593A
Other languages
English (en)
French (fr)
Inventor
Peter A. Anton
Janis V. Giorgi
Michael A. Poles
Julie E. Elliott
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2368593A1 publication Critical patent/CA2368593A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Otolaryngology (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Medicinal Preparation (AREA)
CA002368593A 1999-05-14 2000-05-12 Anti-inflammatory therapy for inflammatory mediated infection Abandoned CA2368593A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13409199P 1999-05-14 1999-05-14
US60/134,091 1999-05-14
PCT/US2000/013142 WO2000069255A1 (en) 1999-05-14 2000-05-12 Anti-inflammatory therapy for inflammatory mediated infection

Publications (1)

Publication Number Publication Date
CA2368593A1 true CA2368593A1 (en) 2000-11-23

Family

ID=22461735

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002368593A Abandoned CA2368593A1 (en) 1999-05-14 2000-05-12 Anti-inflammatory therapy for inflammatory mediated infection

Country Status (13)

Country Link
EP (1) EP1202620A1 (ko)
JP (1) JP2002544210A (ko)
KR (1) KR20020024587A (ko)
CN (1) CN1353573A (ko)
AU (1) AU5010800A (ko)
BR (1) BR0010546A (ko)
CA (1) CA2368593A1 (ko)
HK (1) HK1047216A1 (ko)
IL (1) IL146130A0 (ko)
MX (1) MXPA01011606A (ko)
PL (1) PL351710A1 (ko)
TR (1) TR200103271T2 (ko)
WO (1) WO2000069255A1 (ko)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0302068A3 (en) * 2000-07-20 2005-05-30 Lauras As Use of cox-2 inhibitors for treating or preventing immunodeficiency and pharmaceutical compositions containing them
KR20040072720A (ko) * 2002-01-10 2004-08-18 파마시아 앤드 업존 캄파니 항바이러스제와 함께 사용되는 유두종 바이러스 감염의치료를 위한 ｃｏｘ-2 억제제의 용도
AR039540A1 (es) * 2002-05-13 2005-02-23 Tibotec Pharm Ltd Compuestos microbicidas con contenido de pirimidina o triazina
US6790867B2 (en) * 2002-05-20 2004-09-14 Schering-Plough Animal Health Corporation Compositions and method for treating infection in cattle and swine
CN103143022A (zh) * 2002-07-30 2013-06-12 奥默罗斯公司 眼科冲洗液及方法
ITMI20031311A1 (it) * 2003-06-27 2004-12-28 Indena Spa Formulazioni per il trattamento di disturbi artrosici.
DE602004031356D1 (de) * 2003-11-21 2011-03-24 Zalicus Inc Verfahren und reagenzien zur behandlung von entzündlichen erkrankungen
CN102002476B (zh) * 2010-08-20 2013-05-08 上海市公共卫生临床中心 一种体外培养人体黏膜活组织模型及其建立方法和应用
CN102557976B (zh) * 2010-12-15 2015-06-10 辽宁盛京制药有限公司 溴芬酸有机盐及其制备方法、其组合物及用途
EP2481751A1 (en) * 2011-01-26 2012-08-01 PharmaSurgics in Sweden AB Human lactoferrin derived peptides
AU2013201465B2 (en) 2012-10-24 2016-03-03 Rayner Surgical (Ireland) Limited Stable preservative-free mydriatic and anti-inflammatory solutions for injection
CN104013959A (zh) * 2014-05-21 2014-09-03 郭和友 逆转录抑制剂和免疫抗体细胞三联合疗法
CN105456273A (zh) * 2014-09-02 2016-04-06 杭州雷索药业有限公司 奈韦拉平在制备抗炎药物中的应用
TWI705812B (zh) 2014-12-01 2020-10-01 奥默羅斯公司 用於抑制術後眼睛炎性病況的抗炎和散瞳前房溶液
CN106176739A (zh) * 2016-08-18 2016-12-07 滨州医学院 利托那韦增强糖皮质激素抗炎作用的医药新用途
CN106309445A (zh) * 2016-08-18 2017-01-11 滨州医学院 奈非那韦增强糖皮质激素抗炎作用的医药新用途
CN106176751A (zh) * 2016-08-18 2016-12-07 滨州医学院 茚地那韦增强糖皮质激素抗炎作用的医药新用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605885A (en) * 1988-05-05 1997-02-25 Entremed, Inc. Method for stimulating the immune system
EP0407701A3 (en) * 1989-05-15 1992-04-22 Fujisawa Pharmaceutical Co., Ltd. Antiretroviral pyrroline and pyrrolidine sulfonic acid derivatives
US5891924A (en) * 1996-09-26 1999-04-06 Research Development Foundation Curcumin (diferuloylmethane) inhibition of NFκB activation

Also Published As

Publication number Publication date
AU5010800A (en) 2000-12-05
JP2002544210A (ja) 2002-12-24
KR20020024587A (ko) 2002-03-30
EP1202620A1 (en) 2002-05-08
WO2000069255A1 (en) 2000-11-23
TR200103271T2 (tr) 2002-06-21
CN1353573A (zh) 2002-06-12
MXPA01011606A (es) 2003-09-10
IL146130A0 (en) 2002-07-25
HK1047216A1 (zh) 2003-02-14
BR0010546A (pt) 2002-03-05
PL351710A1 (en) 2003-06-02
WO2000069255A8 (en) 2001-03-22

Similar Documents

Publication Publication Date Title
CA2368593A1 (en) Anti-inflammatory therapy for inflammatory mediated infection
Patterson et al. Repertoire of chemokine receptor expression in the female genital tract: implications for human immunodeficiency virus transmission
Klatt Pathology of AIDS
Utay et al. Role of immune activation in progression to AIDS
Nilsson et al. Early immune activation in gut-associated and peripheral lymphoid tissue during acute HIV infection
Kotler et al. Effect of combination antiretroviral therapy upon rectal mucosal HIV RNA burden and mononuclear cell apoptosis
Schmidt et al. Rapid increase of mucosal CD4 T cells followed by clearance of intestinal cryptosporidiosis in an AIDS patient receiving highly active antiretroviral therapy
US20030138399A1 (en) Anti-inflammatory therapy for inflammatory mediated infection
Shacklett et al. Abundant expression of granzyme A, but not perforin, in granules of CD8+ T cells in GALT: implications for immune control of HIV-1 infection
Shen et al. Mucosal Correlates of Protection in HIV‐1‐Exposed Sero‐negative Persons
Rasmussen et al. Clinical interventions in HIV cure research
NIU et al. Summary of the National Institutes of Health Workshop on Primary Human Immunodeficiency Virus Type 1 Infection1, 2
Johnson et al. Anti-retroviral therapy reverses HIV-associated abnormalities in lymphocyte apoptosis
Van Deventer Anti-TNF antibody treatment of Crohn's disease
Stetson et al. Eosinophilic dermatoses
Krown ACQUIRED IMMUNODEFICIENCY SYNDROME–ASSOCIATED KAPOSI'S SARCOMA: Biology and Management
Sirianni et al. Distribution of the natural killer-related receptor for HLA-C during highly active antiretroviral therapy for human immunodeficiency virus infection
Purohit et al. Potential impact of drugs of abuse on mother-to-child transmission (MTCT) of HIV in the era of highly active antiretroviral therapy (HAART)
US8080579B2 (en) Compositions and methods for treatment of inflammatory bowel disease
Schito et al. A human immunodeficiency virus–transgenic mouse model for assessing interventions that block microbial-induced proviral expression
Nair et al. Association of drug abuse with inhibition of HIV-1 immune responses: studies with long-term of HIV-1 non-progressors
US6387959B1 (en) Antiviral therapy
Wilkinson et al. Immune interventions: The changing face of HIV and AIDS
Edzeamey et al. HIV Infection and Therapeutic Interventions: Review on HIV Infection Biology, Highly Active Antiretroviral Therapy (HAARTs), Hepatotoxicity, Nephrotoxicity and Dyslipidemia
Howard et al. Mucosal challenge with cell‐associated or cell‐free feline immunodeficiency virus induces rapid and distinctly different patterns of phenotypic change in the mucosal and systemic immune systems

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued